Upgrade to SI Premium - Free Trial

CRISPR Therapeutics (CRSP) PT Lowered to $83 at BofA Securities

May 5, 2026 5:12 AM
BofA Securities analyst Alec W. Stranahan lowered the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $83.00 (from $86.00) while ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change